Related Experiment Video
Updated: Jan 19, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Effect of Ceftaroline, Vancomycin, Gentamicin, Macrolides, and Ciprofloxacin against Methicillin-Resistant
Dalia Saad ElFeky1,2, Alaa Reda Awad1, Mustafa Ali Elshobaky3
1Department of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Abstract:
Methicillin-resistant Staphylococcus aureus (MRSA) infection remains a challenging threat because of limited treatment options. Ceftaroline was identified as having potent anti-MRSA activity. To evaluate the susceptibility of MRSA to gentamicin, macrolides, ciprofloxacin, vancomycin, and ceftaroline and to perform molecular characterization of different resistance genes as aminoglycoside modifying enzyme genes, ermA and ermC, and vanA and vanB genes. One hundred non-duplicate MRSA strains were isolated from different samples of hospitalized patients in Cairo University teaching hospitals from November 2015 to August 2016. Determination of antibiotic susceptibility was done using disk diffusion test and minimum inhibitory concentration followed by detection of resistance genes by multiplex polymerase chain reaction (PCR). Of 100 MRSA isolates, 63 (63%) were resistant to gentamicin, erythromycin, clindamycin, and ciprofloxacin, however, all were sensitive to ceftaroline. Fifteen isolates (15%) were vancomycin intermediate resistant and were sensitive to ceftaroline as well. Ceftaroline was potent against MRSA, which was found to be non-susceptible to vancomycin, ciprofloxacin, erythromycin, clindamycin, and gentamicin and it may represent a successful treatment for MRSA infections.
Insights
Ceftaroline shows potent activity against Methicillin-resistant Staphylococcus aureus (MRSA), even strains resistant to other antibiotics. This study confirms ceftaroline as a promising treatment option for challenging MRSA infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant clinical challenge due to limited effective treatment options.
- Ceftaroline has demonstrated potent activity against MRSA in preliminary studies.
Purpose of the Study:
- To assess MRSA susceptibility to gentamicin, macrolides, ciprofloxacin, vancomycin, and ceftaroline.
- To molecularly characterize aminoglycoside modifying enzyme genes, ermA, ermC, vanA, and vanB.
Main Methods:
- 100 non-duplicate MRSA strains were isolated from hospitalized patients.
- Antibiotic susceptibility testing involved disk diffusion and minimum inhibitory concentration assays.
- Resistance genes were detected using multiplex polymerase chain reaction (PCR).
Main Results:
- All 100 MRSA isolates were susceptible to ceftaroline.
- 63% of isolates were resistant to gentamicin, erythromycin, clindamycin, and ciprofloxacin.
- 15% of isolates exhibited intermediate resistance to vancomycin but remained susceptible to ceftaroline.
Conclusions:
- Ceftaroline exhibits potent activity against a wide range of MRSA isolates, including those resistant to conventional therapies.
- Ceftaroline represents a potential effective therapeutic agent for treating MRSA infections, including vancomycin-intermediate strains.
More Related Videos
Related Concept Videos
12:18Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
09:03Multiplex PCR Assay for Typing of Staphylococcal Cassette Chromosome Mec Types I to V in Methicillin-resistant Staphylococcus aureus
08:32Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
03:35In Vitro Biofilm Synthesis by Staphylococcus aureus
06:36Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
10:39Methodology for the Study of Horizontal Gene Transfer in Staphylococcus aureus